Advertisement
News
Advertisement

Seaside Therapeutics research sees possible autism treatment

Wed, 09/19/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

Seaside Therapeutics Inc. in Cambridge Wednesday published its latest research results for its disease-modifying drug candidate STX209 that shows promise as a treatment for fragile X syndrome and autism, the most prevalent form of intellectual disability.

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading